How rare the population at risk of fetal alloimmune thrombocytopaenia really is

Design

prospective, longitudinal, non-interventional natural history study across 28 sites

Population

14,114 pregnant women aged 18 or over with no history of the condition

Primary outcome

alloimmunisation among women meeting all higher-risk criteria

Effect

1.7% HPA-1b/1b; 2 of 19 higher-risk women (11%, 95% CI 1.3% to 33.1%) alloimmunised by 10 weeks postpartum

A prospective natural history study screened 14,114 pregnant women with no history of fetal-neonatal alloimmune thrombocytopaenia across 28 sites in North America and Europe, using a sequential algorithm at 10 to 14 weeks: maternal HPA-1a/1b genotype, HLA-DRB3*01:01 status, anti-HPA-1a antibody status, then fetal HPA-1 genotype.

Of those screened, 1.7% were HPA-1b/1b, with variation by race and geography. Only 24 women met every higher-risk criterion - HPA-1b/1b, DRB3*01:01 positive, antibody negative and carrying an HPA-1a-positive fetus. Five were lost to follow-up; of the remaining 19, two (11%, 95% CI 1.3% to 33.1%) had developed anti-HPA-1a antibodies by 10 weeks postpartum. A separate 18 HPA-1b/1b, DRB3*01:01-positive women already had antibodies at screening.

The number that matters for practice is the funnel: about 1 in 60 women carry the at-risk genotype, and roughly 1 in 600 screened reach the full higher-risk profile. Any universal screening programme would therefore test hundreds to find one candidate for intervention, which is the arithmetic a prophylaxis trial has to beat. For now, suspicion still starts clinically - an unexplained severe neonatal thrombocytopaenia or intracranial bleed, or a previously affected pregnancy.

• Think of alloimmune thrombocytopaenia in unexplained severe neonatal thrombocytopaenia or neonatal intracranial haemorrhage
• Take a history of a previously affected infant - recurrence risk is what drives management
• Send maternal and paternal platelet antigen typing through a reference laboratory, not a local panel
• Do not offer population HPA screening outside a study; the yield does not support it
• Plan delivery and neonatal platelet availability with haematology when a case is known

Why it matters

It puts a number on the screening question: hundreds tested per candidate identified, before any prophylaxis has been shown to work.

Don't overread it

This was non-interventional - it measures how often alloimmunisation happens, not whether detecting it early changes any outcome.

The statistics, in plain English

The alloimmunisation estimate rests on 2 events among 19 women, which is why the confidence interval runs from 1.3% to 33.1% - the true rate could be almost nothing or a third. Numbers this small set the direction of a screening argument, not its magnitude. The 1.7% genotype prevalence, from 14,114 women, is the solid figure in this study.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.